News
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.
Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...
The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Texas Attorney General Ken Paxton alleges that Eli Lilly bribed Texas medical providers to provide the company's drugs. Eli Lilly denies the claims.
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
5h
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback